Certificate of Analysis for NR-52165

Acinetobacter baumannii, Strain MRSN 4484

Catalog No. NR-52165

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 4484 was isolated in 2011 from a human tissue sample in the USA as part of a global surveillance program. *A. baumannii*, strain MRSN 4484 was deposited as sensitive to colistin and resistant to amikacin, ceftazidime, ciprofloxacin, ceftriaxone, cefepime, gentamicin, imipenem, trimethoprim/sulfamethoxazole, levofloxacin, meropenem, tetracycline, tobramycin and ampicillin/sulbactam. NR-52165 was produced by inoculation of BEI Resources seed lot 70038546 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70051018 **Manufacturing Date: 09MAR2022**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream
Growth at 44°C ± 2°C[1] 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility Remel™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Non-motile
VITEK® MS (MALDI-TOF)	*A. baumannii*	*A. baumannii* (99.9%)
Antibiotic Susceptibility Profile[2,3]		
Amikacin	Resistant	Resistant (≥ 256 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (48 µg/mL)
Cefepime	Resistant	Resistant (32 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Colistin	Sensitive	Sensitive (≤ 0.25 µg/mL)[4]
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Resistant	Resistant (32 µg/mL)
Levofloxacin	Resistant	Intermediate (4 µg/mL)[5]
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Tetracycline	Resistant	Resistant (≥ 16 µg/mL)
Tobramycin	Resistant	Sensitive (≤ 1 µg/mL)[6]
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1480 base pairs)	≥ 99% sequence identity to *A. baumannii*, strain MRSN 4484 (GenBank: VHER01000112.1)	99.9% sequence identity to *A. baumannii*, strain MRSN 4484 (GenBank: VHER01000112.1)

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Certificate of Analysis for NR-52165

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO_2 on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

[1]Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus and A. pittii*, which do not grow at 44°C.
[2]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[3]Antibiotic susceptibility was tested using a combination of VITEK®2 GN82, Sensititre GNX2F AST and E-test strips.
[4]Testing was performed on BEI Resources seed lot 70038546.
[5]The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.
[6]*A. baumannii*, strain MRSN 4484 was deposited as resistant to tobramycin, but showed a MIC of ≤ 1 µg per mL (interpreted as sensitive) for this antibiotic during QC testing. Testing was performed in duplicate.

/Sonia Bjorum Brower/
Sonia Bjorum Brower 30 AUG 2022
Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898